Comparative Pharmacology
Head-to-head clinical analysis: PREDNISONE INTENSOL versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREDNISONE INTENSOL versus TEXACORT.
PREDNISONE INTENSOL vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
5-60 mg orally once daily or divided twice daily, titrated to response.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category D/X
Category C
Corticosteroid
Corticosteroid